FIGURE

Fig. 4

ID

ZDB-FIG-120126-71

Publication

Nguyen et al., 2012 - An inducible krasV12 transgenic zebrafish model for liver tumorigenesis and chemical drug screening

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

Suppression of liver tumorigenesis by inhibition of the Raf-MEK-ERK and PI3K-AKT-mTOR pathways. (A) Fluorescent images showing representative mifepristone-induced EGFP-kras^V12 driver-effector larvae at 7 dpf treated with different inhibitors, as compared with the DMSO-treated driver and driver-effector transgenics as controls. Scale bar: 200 μm. (B) Comparison of the anti-HL effect of inhibitors in transgenic larvae at 7 dpf. The liver size of treated larvae was classified as ‘normal’ if it was the same as the liver in driver transgenics, ‘huge’ if it remained enlarged/hyperplasia, or ‘large’ if it was larger than normal liver, but smaller than hyperplasia after 4 days of inhibitor treatment. (C) Lysates extracted from whole transgenic larvae treated with the indicated inhibitors were immunoblotted for phospho-ERK (P-ERK), P-AKT and P-S6. β-actin, internal control for equal loading. (D) Proposed inhibitor treatments to suppress Kras^V12-induced liver tumorigenesis via targeting both the Raf-MEK-ERK and PI3K-AKT-mTOR pathways.

Expression Data

Genes:	EGFP mCherry
Fish:	gz23Tg gz23Tg; gz24Tg
Conditions:	chemical treatment: mifepristone chemical treatment: pharmaceutical chemical treatment: pharmaceutical chemical treatment: sirolimus
Anatomical Terms:	lens liver
Stage:	Days 7-13

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Dis. Model. Mech.